The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

Alchemab Therapeutics Ltd. has entered into a licensing agreement with Eli Lilly and Co. for ATLX-1282, Alchemab’s first-in-class IND-ready program targeting a novel receptor and mechanism for ...

Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company May 06, 2025 3:30 AM ET ...

Deals: Merck Animal Health and Kansas announced a $895 million investment in manufacturing as well as research and development facilities in De Soto. Eli Lil­ly is set to pay up to $415 million in an ...

Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company By Alchemab Therapeutics May 6, 2025 Updated May 6, 2025 ...

Article ‘Count’ and ‘Share’ for Alchemab Therapeutics Ltd. based on listed parameters only. The articles listed below published by authors from Alchemab Therapeutics Ltd., organized by ...

Alchemab’s advanced analytics to be used to analyse patient immune responses, identify natural mechanisms of protection and novel drug targets, and predict patient responsiveness ...